Transplant characteristics of children with AML given an unrelated cord blood transplant
Unrelated cord blood characteristics . | . |
|---|---|
| HLA compatibility with the recipient (%) | |
| High-resolution typing+ | |
| No. evaluable | 93/95 |
| Identical | 8 (9) |
| 1 HLA disparity | 44 (47) |
| 2 HLA disparities | 31 (33) |
| 3 or more HLA disparities | 10 (11) |
| Low-resolution typing+ | |
| No. evaluable | 95/95 |
| Identical | 13 (14) |
| 1 HLA disparity | 52 (55) |
| 2 HLA disparities | 28 (29) |
| 3 HLA disparities | 2 (2) |
| ABO compatibility with the recipient | |
| No. evaluable | 94/95 |
| Matched | 45 |
| Minor incompatibility | 24 |
| Major incompatibility | 25 |
| Nucleated cells collected/kg recipient | |
| No. evaluable | 92/95 |
| Median (range) | 5.2 × 107 (1.2 × 107-46.6 × 107) |
| Nucleated cells infused/kg recipient | |
| No. evaluable | 94/95 |
| Median (range) | 4.4 × 107 (0.4 × 107-36 × 107) |
| CD34 infused cells/kg recipient | |
| No. evaluable | 60/95 |
| Median (range) | 1.38 × 105 (0.4 × 105-78 × 105) |
| Transplantation characteristics | |
| Conditioning regimen (%) | |
| TBI-containing | 44 (46.5) |
| Bu-containing | 47 (49.5) |
| Miscellaneous | 4 (4) |
| Pretransplantation ATG/ALG or anti-T | 72 (76) |
| MoAb (%) | |
| Posttransplantation growth factor, started D0-D+7 (%) | 47 (50) |
| GVHD prophylaxis (%) | |
| Including cyclosporine A | 85 (89.5) |
| + steroids | 63 (66) |
| + MTX | 20 (21) |
| Tacrolimus + MTX | 7 (7.5) |
| Miscellaneous | 3 (3) |
Unrelated cord blood characteristics . | . |
|---|---|
| HLA compatibility with the recipient (%) | |
| High-resolution typing+ | |
| No. evaluable | 93/95 |
| Identical | 8 (9) |
| 1 HLA disparity | 44 (47) |
| 2 HLA disparities | 31 (33) |
| 3 or more HLA disparities | 10 (11) |
| Low-resolution typing+ | |
| No. evaluable | 95/95 |
| Identical | 13 (14) |
| 1 HLA disparity | 52 (55) |
| 2 HLA disparities | 28 (29) |
| 3 HLA disparities | 2 (2) |
| ABO compatibility with the recipient | |
| No. evaluable | 94/95 |
| Matched | 45 |
| Minor incompatibility | 24 |
| Major incompatibility | 25 |
| Nucleated cells collected/kg recipient | |
| No. evaluable | 92/95 |
| Median (range) | 5.2 × 107 (1.2 × 107-46.6 × 107) |
| Nucleated cells infused/kg recipient | |
| No. evaluable | 94/95 |
| Median (range) | 4.4 × 107 (0.4 × 107-36 × 107) |
| CD34 infused cells/kg recipient | |
| No. evaluable | 60/95 |
| Median (range) | 1.38 × 105 (0.4 × 105-78 × 105) |
| Transplantation characteristics | |
| Conditioning regimen (%) | |
| TBI-containing | 44 (46.5) |
| Bu-containing | 47 (49.5) |
| Miscellaneous | 4 (4) |
| Pretransplantation ATG/ALG or anti-T | 72 (76) |
| MoAb (%) | |
| Posttransplantation growth factor, started D0-D+7 (%) | 47 (50) |
| GVHD prophylaxis (%) | |
| Including cyclosporine A | 85 (89.5) |
| + steroids | 63 (66) |
| + MTX | 20 (21) |
| Tacrolimus + MTX | 7 (7.5) |
| Miscellaneous | 3 (3) |
TBI indicates total body irradiation; Bu, Busulfan; ATG, antithymocyte globulin; ALG, antilymphocyte globulin; MoAb, monoclonal antibody; D0-D+7, day 0 to day 7 after graft infusion; and MTX, methotrexate.